Literature DB >> 15273990

The PARP superfamily.

Jean-Christophe Amé1, Catherine Spenlehauer, Gilbert de Murcia.   

Abstract

Poly(ADP-ribosyl)ation is an immediate DNA-damage-dependent post-translational modification of histones and other nuclear proteins that contributes to the survival of injured proliferating cells. Poly(ADP-ribose) polymerases (PARPs) now constitute a large family of 18 proteins, encoded by different genes and displaying a conserved catalytic domain in which PARP-1 (113 kDa), the founding member, and PARP-2 (62 kDa) are so far the sole enzymes whose catalytic activity has been shown to be immediately stimulated by DNA strand breaks. A large repertoire of sequences encoding novel PARPs now extends considerably the field of poly(ADP-ribosyl)ation reactions to various aspects of the cell biology including cell proliferation and cell death. Some of these new members interact with each other, share common partners and common subcellular localizations suggesting possible fine tuning in the regulation of this post-translational modification of proteins. This review summarizes our present knowledge of this emerging superfamily, which might ultimately improve pharmacological strategies to enhance both antitumor efficacy and the treatment of a number of inflammatory and neurodegenerative disorders. A provisional nomenclature is proposed.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15273990     DOI: 10.1002/bies.20085

Source DB:  PubMed          Journal:  Bioessays        ISSN: 0265-9247            Impact factor:   4.345


  509 in total

1.  A Phase I, dose-finding and pharmacokinetic study of olaparib (AZD2281) in Japanese patients with advanced solid tumors.

Authors:  Noboru Yamamoto; Hiroshi Nokihara; Yasuhide Yamada; Yasushi Goto; Maki Tanioka; Takashi Shibata; Kazuhiko Yamada; Hajime Asahina; Toshio Kawata; Xiaojin Shi; Tomohide Tamura
Journal:  Cancer Sci       Date:  2012-01-30       Impact factor: 6.716

2.  Endogenous protein mono-ADP-ribosylation in Arabidopsis thaliana.

Authors:  Hai Wang; Qin Liang; Kaiming Cao; Xiaochun Ge
Journal:  Planta       Date:  2011-04-26       Impact factor: 4.116

3.  Association between PARP-1 V762A polymorphism and cancer susceptibility: a meta-analysis.

Authors:  Hongping Yu; Hongxia Ma; Ming Yin; Qingyi Wei
Journal:  Genet Epidemiol       Date:  2011-11-29       Impact factor: 2.135

Review 4.  Mitochondrial dysfunction and NAD(+) metabolism alterations in the pathophysiology of acute brain injury.

Authors:  Katrina Owens; Ji H Park; Rosemary Schuh; Tibor Kristian
Journal:  Transl Stroke Res       Date:  2013-08-10       Impact factor: 6.829

5.  Functional localization of two poly(ADP-ribose)-degrading enzymes to the mitochondrial matrix.

Authors:  Marc Niere; Stefan Kernstock; Friedrich Koch-Nolte; Mathias Ziegler
Journal:  Mol Cell Biol       Date:  2007-11-08       Impact factor: 4.272

6.  Specific Binding of snoRNAs to PARP-1 Promotes NAD+-Dependent Catalytic Activation.

Authors:  Dan Huang; Dae-Seok Kim; W Lee Kraus
Journal:  Biochemistry       Date:  2020-04-17       Impact factor: 3.162

7.  Phosphorylation of p53 by TAF1 inactivates p53-dependent transcription in the DNA damage response.

Authors:  Yong Wu; Joy C Lin; Landon G Piluso; Joseph M Dhahbi; Selene Bobadilla; Stephen R Spindler; Xuan Liu
Journal:  Mol Cell       Date:  2013-11-27       Impact factor: 17.970

Review 8.  Beyond chemotherapy: targeted therapies in ovarian cancer.

Authors:  Timothy A Yap; Craig P Carden; Stan B Kaye
Journal:  Nat Rev Cancer       Date:  2009-03       Impact factor: 60.716

9.  Base excision repair defects invoke hypersensitivity to PARP inhibition.

Authors:  Julie K Horton; Donna F Stefanick; Rajendra Prasad; Natalie R Gassman; Padmini S Kedar; Samuel H Wilson
Journal:  Mol Cancer Res       Date:  2014-04-25       Impact factor: 5.852

Review 10.  Mitochondrial and nuclear cross talk in cell death: parthanatos.

Authors:  Shaida A Andrabi; Ted M Dawson; Valina L Dawson
Journal:  Ann N Y Acad Sci       Date:  2008-12       Impact factor: 5.691

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.